DK1854477T3 - Peptidinhibitorer af plasmakallikrein til anvendelse til behandling af øjenforstyrrelser - Google Patents

Peptidinhibitorer af plasmakallikrein til anvendelse til behandling af øjenforstyrrelser Download PDF

Info

Publication number
DK1854477T3
DK1854477T3 DK07005182.6T DK07005182T DK1854477T3 DK 1854477 T3 DK1854477 T3 DK 1854477T3 DK 07005182 T DK07005182 T DK 07005182T DK 1854477 T3 DK1854477 T3 DK 1854477T3
Authority
DK
Denmark
Prior art keywords
phe
cys
glu
gly
ala
Prior art date
Application number
DK07005182.6T
Other languages
English (en)
Inventor
Pierre Belichard
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DK1854477T3 publication Critical patent/DK1854477T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (19)

1. Sammensætning, der omfatter mindst ét peptid, der inhiberer plasmakallikrein, til anvendelse til behandling af øjenforstyrrelser hos en patient, der har brug for dette.
2. Sammensætning til anvendelse ifølge krav 1, hvor peptidet er et Kunitz-domænepolypeptid.
3. Sammensætning til anvendelse ifølge krav 1 eller 2, hvor peptidet indbefatter aminosyresekvensen: Xaal Xaa2 Xaa3 Xaa4 Cys Xaa6 Xaa7 Xaa8 Xaa9 XaalO Xaall Gly Xaal3 Cys Xaal5 Xaal6 Xaal7 Xaal8 Xaal9 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25 Xaa26 Xaa27 Xaa28 Xaa29 Cys Xaa31 Xaa32 Phe Xaa34 Xaa35 Gly Gly Cys Xaa39 Xaa40 Xaa41 Xaa42 Xaa43 Xaa44 Xaa45 Xaa46 Xaa47 Xaa48 Xaa49 Xaa50 Cys Xaa52 Xaa53 Xaa54 Cys Xaa56 Xaa57 Xaa58 (SEQ ID NO: 1), hvor Xaa'erne uafhængigt af hinanden er en hvilken som helst aminosyre.
4. Sammensætning til anvendelse ifølge krav 3, hvor et eller flere af følgende gælder: Xaal, Xaa2, Xaa3, Xaa4, Xaa56, Xaa57 eller Xaa58 uafhængigt af hinanden er en hvilken som helst aminosyre eller fraværende; XaalO er en aminosyre udvalgt fra gruppen, der består af Asp og Glu; Xaall er en aminosyre udvalgt fra gruppen, der består af Asp, Gly, Ser, Val, Asn, Ile, Ala og Thr; Xaal3 er en aminosyre udvalgt fra gruppen, der består af Arg, His, Pro, Asn, Ser, Thr, Ala, Gly, Lys og Gin; Xaal5 er en aminosyre udvalgt fra gruppen, der består af Arg, Lys, Ala, Ser, Gly, Met, Asn og Gin; Xaal6 er en aminosyre udvalgt fra gruppen, der består af Ala, Gly, Ser, Asp og Asn; Xaal7 er en aminosyre udvalgt fra gruppen, der består af Ala, Asn, Ser, Ile, Gly, Val, Gin og Thr, Xaal8 er en aminosyre udvalgt fra gruppen, der består af His, Leu, Gin og Ala; Xaal9 er en aminosyre udvalgt fra gruppen, der består af Pro, Gin, Leu, Asn og lie; Xaa21 er en aminosyre udvalgt fra gruppen, der består af Trp, Phe, Tyr, His og Ile; Xaa22 er en aminosyre udvalgt fra gruppen, der består af Tyr og Phe; Xaa23 er en aminosyre udvalgt fra gruppen, der består af Tyr og Phe; Xaa31 er en aminosyre udvalgt fra gruppen, der består af Glu, Asp, Gin, Asn, Ser, Ala, Val, Leu, Ile og Thr, Xaa32 er en aminosyre udvalgt fra gruppen, der består af Glu, Gin, Asp Asn, Pro, Thr, Leu, Ser, Ala, Gly og Val; Xaa34 er en aminosyre udvalgt fra gruppen, der består af Thr, Ile, Ser, Val, Ala, Asn, Gly og Leu; Xaa35 er en aminosyre udvalgt fra gruppen, der består af Tyr, Trp og Phe; Xaa39 er en aminosyre udvalgt fra gruppen, der består af Glu, Gly, Ala, Ser og Asp; Xaa40 er en aminosyre udvalgt fra gruppen, der består af Gly og Ala; Xaa43 er en aminosyre udvalgt fra gruppen, der består af Asn og Gly; Xaa45 er en aminosyre udvalgt fra gruppen, der består af Phe og Tyr; Xaa6, Xaa7, Xna8, Xna9, Xnn20, Xna24, Xna25, Xna26, Xnn27, Xaa28, Xaa29, Xaa41, Xaa42, Xaa44, Xaa46, Xaa47, Xaa48, Xaa49, Xaa50, Xaa52, Xaas53 og Xaa54 uafhængigt af hinanden er en hvilken som helst aminosyre.
5. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor peptidet er udvalgt fra gruppen, der består af: Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Arg Ala Ala His Pro Arg Trp Phe Phe Asn Ile Phe Thr Arg Gin Cys Glu Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ DD No:2), Met His Ser Phe Cys Ala Phe Lys AlaXaalO Xaall Gly Xaal3 Cys Xaal5 Xaal6 Xaal7 Xaal8 Xaal9 Arg Xaa21 Phe Phe Asn Ile Phe Thr Arg Gin Cys Xaa31 Xaa32 Phe Xaa34 Xaa35 Gly Gly Cys Xaa39 Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID No:3), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Lys Ala Asn His Leu Arg Phe Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin AsnArg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr ArgAsp (SEQ ID No:4), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Ala Asn His Gin Arg Phe Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe Thr Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID No:5), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Ala Asn His Gin Arg Phe Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Gin Phe Thr Tyr Gly Gly Cys Ala Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID No:6), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Ala Ser Leu Pro Arg Phe Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe lie Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO:7), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Ala Asn His Gin Arg Phe Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID No:8), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Gly Ala His Leu Arg Phe Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe lie Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID No:9), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Aig Cys Lys Gly Ala His Leu Arg Phe Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe lie Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO: 10), Met His Ser Phe Cys Ala Phe Lys Ala Asp Gly Gly Arg Cys Arg Gly Ala His Pro Aig Trp Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO: 11), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Aig Ala Ala His Pro Aig Trp Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO:i2), Met His Ser Phe Cys Ala Phe Lys Ala Asp Val Gly Aig Cys Aig Gly Ala His Pro Aig Tip Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO: 13), Met His Ser Phe Cys Ala Phe Lys Ala Asp Val Gly Arg Cys Aig Gly Ala Gin Pro Arg Phe Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO: 14), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Ser Cys Aig Ala Ala His Leu Aig Trp Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Aig Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ IDNo:i5), Met His Ser Phe Cys Ala Phe Lys Ala Glu Gly Gly Ser Cys Aig Ala Ala His Gin Arg Trp Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO:i6), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro (¾¾ Arg Gly Ala His Leu Aig Phe Phe Phe Asn He Phe Thr Aig Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO: 17), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Aig Gly Ala Leu Pro Arg Trp Phe Phe Asn Ile Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO:i8), Met His Ser Phe Cys Ala Phe Lys Ala Asp Ser Gly Asn (¾¾ Arg Gly Asn Leu Pro Arg Phe Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO: 19), Met His Ser Phe Cys Ala Phe Lys Ala Asp Ser Gly Arg Cys Arg Gly Asn His Gin Arg Phe Phe Phe Asn lie Phe Thr Aig Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO:20), Met His Ser Phe Cys Ala Phe Lys Ala Asp Gly Gly Aig Cys Arg Ala He Gin Pro Aig Trp Phe Phe Asn lie Phe Thr Aig Gin Cys Glu Glu Phe Ser Tyr Gly Gly (¾¾ Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID N0:2i), Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Aig Cys Arg Gly Ala His Pro Arg Trp Phe Phe Asn lie Phe Thr Aig Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Aig Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID N0:22). Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Aig Ala Ala His Pro Arg Trp Phe Phe Asn lie Phe Thr Aig Gin (¾¾ Glu Glu Phe lie Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID N0:23), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Xaaio Xaaii Gly Xaai3 Cys Xaais Xaai6 Xaai7 Xaai8 Xaai9 ArgXaa2i Phe Phe Asn He Phe Thr Arg Gin Cys Xaa3i Xaa32 Phe Xaa34 Xaa35 Gly Gly Cys Xaa39 Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID N0:24), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Lys Ala Asn His Leu Arg Phe Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID N0:25), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Ala Asn His Gin Arg Phe Phe Phe Asn lie Phe Thr Aig Gin Cys Glu Glu Phe Thr Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO.26), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Ala Asn His Gin Arg Phe Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Gin Phe Thr Tyr Gly Gly Cys Ala Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID N0:27), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Ala Ser Leu Pro Arg Phe Phe Phe Asn Ile Phe Thr Aig Gin Cys Glu Glu Phe He Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID N0:28), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Ala Asn His Gin Arg Phe Phe Phe Asn He Phe Thr Arg Gin C|ys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID N0:29), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Lys Gly Ala His Leu Arg Phe Phe Phe Asn Ile Phe Thr Arg Gin Cys Glu Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID N0:3O), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Arg Cys Lys Gly Ala His Leu Arg Phe Phe Phe Asn lie Phe Thr Aig Gin Cys Glu Glu Phe He Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID No:3i), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Gly Gly Aig Cys Arg Gly Ala His Pro Arg Trp Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO.32)) Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Aig Ala Ala His Pro Aig Trp Phe Phe Asn Ile Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO-33), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Val Gly Aig Cys Arg Gly Ala His Pro Arg Tip Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Aig Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO:34), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Val Gly Aig Cys Arg Gly Ala Gin Pro Arg Phe Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO-35), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Ser Cys Arg Ala Ala His Leu Arg Trp Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Aig Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO-36), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Glu Gly Gly Ser Cys Aig Ala Ala His Gin Arg Trp Phe Phe Asn lie Phe Thr Aig Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO-37), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Aig Gly Ala His Leu Arg Phe Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO:38), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly His Cys Aig Gly Ala Leu Pro Arg Trp Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO:39). Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Ser Gly Asn Cys Aig Gly Asn Leu Pro Arg Phe Phe Phe Asn He Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Aig Asp (SEQ ID NO:40), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Ser Gly Aig Cys Arg Gly Asn His Gin Arg Phe Phe Phe Asn De Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO:4i), Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Gly Gly Arg Cys Aig Ala lie Gin Pro Arg Trp Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID N0:42), og Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Arg Cys Arg Gly Ala His Pro Arg Trp Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO:43).
6. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor peptidet er Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Arg Ala Ala His Pro Arg Trp Phe Phe Asn Ile Phe Thr Arg Gin Cys Glu Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO: 23).
7. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor ø j enf orstyrrelsen er en exsudativ eller inflammatorisk øjenforstyrrelse.
8. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor øj enf orstyrrelsen er forbundet med nedsat retinal karpermeabilitet eller -integritet.
9. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor øj enf orstyrrelsen er en sygdom bag i øjet.
10. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor øjenforstyrrelsen omfatter makulært ødem.
11. Sammensætning til anvendelse ifølge krav 10, hvor peptidet er Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Arg Ala Ala His Pro Arg Trp Phe Phe Asn Ile Phe Thr Arg Gin Cys Glu Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO: 23) .
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor øjenforstyrrelsen omfatter retinal veneokklusion.
13. Sammensætning til anvendelse ifølge krav 12, hvor peptidet er Glu Ala Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Arg Ala Ala His Pro Arg Trp Phe Phe Asn Ile Phe Thr Arg Gin Cys Glu Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID NO: 23).
14. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 13, der omfatter en fysiologisk saltvandsopløsning.
15. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 14, hvor sammensætningen er udformet til administration i kombination med en anden terapi.
16. Sammensætning til anvendelse ifølge krav 15, hvor den anden terapi er udvalgt fra gruppen, der består af: fotodynamisk terapi, laserkirurgi, laserfotokoagulation, en biologisk behandling og en farmaceutisk behandling.
17. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor sammensætningen omfatter et anti-angiogent middel.
18. Sammensætning til anvendelse ifølge krav 17, hvor det anti-angiogene middel blokerer aktiviteten af VEGF på endotelceller.
19. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 1 til 18 til fremstilling af et medikament til behandling af øjenforstyrrelser hos en patient, der har brug for dette.
DK07005182.6T 2006-03-16 2007-03-13 Peptidinhibitorer af plasmakallikrein til anvendelse til behandling af øjenforstyrrelser DK1854477T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360008 2006-03-16
EP06291516 2006-09-26

Publications (1)

Publication Number Publication Date
DK1854477T3 true DK1854477T3 (da) 2016-11-28

Family

ID=38292592

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07005182.6T DK1854477T3 (da) 2006-03-16 2007-03-13 Peptidinhibitorer af plasmakallikrein til anvendelse til behandling af øjenforstyrrelser

Country Status (12)

Country Link
US (3) US20070270344A1 (da)
JP (2) JP5337493B2 (da)
AU (1) AU2007224643B2 (da)
CA (1) CA2646285C (da)
DK (1) DK1854477T3 (da)
ES (2) ES2682646T3 (da)
HU (2) HUE031701T2 (da)
LT (2) LT2374472T (da)
PL (1) PL1854477T3 (da)
PT (2) PT2374472T (da)
SI (1) SI2374472T1 (da)
WO (1) WO2007104541A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP2500031A3 (en) * 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
EP1981538B1 (en) 2005-12-30 2014-09-17 Dyax Corporation Metalloproteinase binding proteins
HUE031701T2 (en) 2006-03-16 2017-07-28 Dyax Corp Plasma kallikrein inhibiting peptides for use in treating eye diseases
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US8147836B2 (en) 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
AU2009308369A1 (en) * 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
CN102307594A (zh) 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
HUE039605T2 (hu) 2010-01-06 2019-01-28 Dyax Corp Plazma kallikreint kötõ proteinek
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
GB2510407A (en) * 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
CA2906624A1 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
CA2927554C (en) 2013-10-28 2022-11-29 Bicycle Therapeutics Limited Novel polypeptides
CA2937329C (en) 2014-01-21 2022-05-31 Dyax Corp. Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
WO2015148790A1 (en) * 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
ES2924486T3 (es) * 2015-11-18 2022-10-07 Univ Louisville Res Found Inc Procedimientos automatizados para la cuantificación objetiva de las características de la retina por región retiniana y el diagnóstico de la patología retiniana
RU2622031C1 (ru) * 2015-12-07 2017-06-08 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ комбинированного лечения макулярного отека сетчатки
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
CA3136326A1 (en) * 2019-04-08 2020-10-15 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
LT6899B (lt) * 2020-08-27 2022-04-11 Valstybinis mokslinių tyrimų institutas Fizinių ir technologijos mokslų centras Vario paviršiaus cheminio nikeliavimo būdas, nenaudojant aktyvavimo paladžiu
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
CA2180954C (en) * 1994-01-11 2007-03-20 William Markland Inhibitors of human plasmin derived from the kunitz domains
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
JP3805785B2 (ja) * 1994-01-11 2006-08-09 ダイアックス コープ． カリクレイン阻害クニッツドメイン蛋白質およびその相同体
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
DE10060653A1 (de) * 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
KR20110014661A (ko) 2002-02-07 2011-02-11 노보자임스 바이오파마 디케이 에이/에스 알부민-융합 쿠니츠 도메인 펩타이드
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2003103475A2 (en) * 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
SI2386310T1 (sl) * 2002-08-28 2019-03-29 Dyax Corp. Metode za ohranjanje organov in tkiv
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
CA2537113A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
CA2643693A1 (en) 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
HUE031701T2 (en) * 2006-03-16 2017-07-28 Dyax Corp Plasma kallikrein inhibiting peptides for use in treating eye diseases
US8467792B2 (en) * 2006-06-27 2013-06-18 Qualcomm Incorporated Method and apparatus for maintaining call continuity in wireless communication
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US20090105142A1 (en) * 2007-08-23 2009-04-23 Genzyme Corporation Treatment with kallikrein inhibitors
AU2009308369A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders

Also Published As

Publication number Publication date
WO2007104541A2 (en) 2007-09-20
JP5337493B2 (ja) 2013-11-06
US9107928B2 (en) 2015-08-18
WO2007104541A3 (en) 2008-06-26
PL1854477T3 (pl) 2017-02-28
US20100273721A1 (en) 2010-10-28
AU2007224643B2 (en) 2012-10-11
SI2374472T1 (sl) 2018-11-30
JP2009529553A (ja) 2009-08-20
ES2601554T3 (es) 2017-02-15
HUE031701T2 (en) 2017-07-28
US20070270344A1 (en) 2007-11-22
PT2374472T (pt) 2018-08-08
CA2646285A1 (en) 2007-09-20
PT1854477T (pt) 2016-11-10
AU2007224643A1 (en) 2007-09-20
LT1854477T (lt) 2016-12-12
CA2646285C (en) 2020-04-28
JP2012211194A (ja) 2012-11-01
LT2374472T (lt) 2018-09-25
HUE039108T2 (hu) 2018-12-28
US20150368359A1 (en) 2015-12-24
ES2682646T3 (es) 2018-09-21

Similar Documents

Publication Publication Date Title
DK1854477T3 (da) Peptidinhibitorer af plasmakallikrein til anvendelse til behandling af øjenforstyrrelser
EP1755616B1 (en) Treatment of exudative retinopathy with mineralcorticoids
US20070196350A1 (en) Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
JP2007523911A (ja) 眼病変治療用テトラサイクリン誘導体
US20050261243A1 (en) Antiprostaglandins for the treatment of ocular pathologies
CN115066236A (zh) 糖尿病性黄斑水肿和视敏度受损的治疗
EP1854477B9 (en) Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders.
Kuppermann et al. Drug delivery to the posterior segment of the eye
Ianchulev Suprachoroidal space as a therapeutic target
JP2007500250A (ja) 病的な眼の新脈管形成を処置するための非ステロイド性抗炎症剤の処方物
JP2007500250A5 (da)
AU2005232693B2 (en) Treatment of ophthalmic conditions with mineralcorticoids
WO2023144030A1 (en) Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) Biomarker for plasma kallikrein inhibitor therapy response
AU2005216569A1 (en) Heparin for the treatment of ocular pathologies